Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination

被引:43
作者
Ye, Yumei
Lin, Yu
Perez-Polo, Regino
Huang, Ming-He
Hughes, Michael G.
McAdoo, David J.
Manickavasagam, Saraswathy
Uretsky, Barry F.
Birnbaum, Yochai
机构
[1] Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA
[2] Univ Texas, Med Branch, Dept Biochem, Galveston, TX 77550 USA
[3] Univ Texas, Med Branch, Dept Biol Mol, Galveston, TX 77550 USA
[4] Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77550 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2007年 / 293卷 / 01期
关键词
adenosine; Akt; infarct size; nitric oxide synthase;
D O I
10.1152/ajpheart.00210.2007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atorvastatin (ATV) limits infarct size (IS) by activating Akt and ecto-5-nucleotidase, which generates adenosine. Activated Akt and adenosine activate endothelial nitric oxide synthase (eNOS). When given orally, high doses (10 mg/kg) are needed to achieve full protection. We determined whether dipyridamole (DIP), by preventing the reuptake of adenosine, has a synergistic effect with ATV in reducing myocardial IS. In this study, rats received 3-days of the following: water, ATV (2 mg center dot kg(-1) center dot day(-1)), DIP (6 mg center dot kg(-1)center dot day(-1)), or ATV + DIP. In addition, rats received 3-days of the following: aminophylline (Ami; 10 mg center dot kg(-1)center dot day(-1)) or Ami + ATV + DIP. Rats underwent 30 min of myocardial ischemia followed by 4 h of reperfusion (IS protocol), or hearts were explanted for immunoblotting. As a result, IS in the controls was 34.0 +/- 2.8% of the area at risk. ATV (33.1 +/- 2.1%) and DIP (30.5 +/- 1.5%) did not affect IS, whereas ATV + DIP reduced IS (12.2 +/- 0.5%; P < 0.001 vs. each of the other groups). There was no difference in IS between the Ami alone (48.1 +/- 0.8%) and the Ami + ATV + DIP (45.8 +/- 2.9%) group (P = 0.422), suggesting that Ami completely blocked the protective effect. Myocardial adenosine level in the controls was 30.6 +/- 3.6 pg/mu l. ATV (51.0 +/- 4.9 pg/mu l) and DIP (51.5 +/- 6.8 pg/mu l) caused a small increase in adenosine levels, whereas ATV + DIP caused a greater increase in adenosine levels (66.4 +/- 3.1 pg/mu l). ATV and DIP alone did not affect myocardial Ser473 phosphorylated-Akt and Ser1177 phosphorylated-eNOS levels, whereas ATV + DIP significantly increased them. In conclusion, low-dose ATV and DIP had synergistic effects in reducing myocardial IS and activation of Akt and eNOS. This combination may have a potential benefit in augmenting the eNOS-mediated pleiotropic effects of statins.
引用
收藏
页码:H813 / H818
页数:6
相关论文
共 54 条
  • [1] Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice
    Amin-Hanjani, S
    Stagliano, NE
    Yamada, M
    Huang, PL
    Liao, JK
    Moskowitz, MA
    [J]. STROKE, 2001, 32 (04) : 980 - 985
  • [2] Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2
    Atar, S
    Ye, YM
    Lin, Y
    Freeberg, SY
    Nishi, SP
    Rosanio, S
    Huang, MH
    Uretsky, BF
    Perez-Polo, JR
    Birnbaum, Y
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (05): : H1960 - H1968
  • [3] ADENOSINE-A(1) RECEPTORS, K(ATP) CHANNELS, AND ISCHEMIC PRECONDITIONING IN DOGS
    AUCHAMPACH, JA
    GROSS, GJ
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 264 (05): : H1327 - H1336
  • [4] Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway
    Bell, RM
    Yellon, DM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (03) : 508 - 515
  • [5] Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury
    Birnbaum, Y
    Ye, YM
    Rosanio, S
    Tavackoli, S
    Hu, ZY
    Schwarz, ER
    Uretsky, BF
    [J]. CARDIOVASCULAR RESEARCH, 2005, 65 (02) : 345 - 355
  • [6] Reduction of infarct size by short-term pretreatment with atorvastatin
    Birnbaum, Y
    Ashitkov, T
    Uretsky, BF
    Ballinger, S
    Motamedi, M
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2003, 17 (01) : 25 - 30
  • [7] BIRNBAUM Y, 2006, CIRC RES, V99, pE26
  • [8] Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin
    Birnbaum, Yochai
    Lin, Yu
    Ye, Yumei
    Martinez, Juan D.
    Huang, Ming-He
    Lui, Charles Y.
    Perez-Polo, Jose R.
    Uretsky, Barry F.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2007, 292 (06): : H2891 - H2897
  • [9] Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat
    Birnbaum, Yochai
    Ye, Yumei
    Lin, Yu
    Freeberg, Sheldon Y.
    Nishi, Shawn P.
    Martinez, Juan D.
    Huang, Ming-He
    Uretsky, Barry F.
    Perez-Polo, Jose R.
    [J]. CIRCULATION, 2006, 114 (09) : 929 - 935
  • [10] Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins
    Brouet, A
    Sonveaux, P
    Dessy, C
    Moniotte, S
    Balligand, JL
    Feron, O
    [J]. CIRCULATION RESEARCH, 2001, 89 (10) : 866 - 873